The Analyst Verdict: Edwards Lifesciences In The Eyes Of 21 Experts
Analysts' ratings for Edwards Lifesciences (NYSE:EW) over the last quarter vary from bullish to bearish, as provided by 21 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 6 | 7 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 1 | 0 | 0 |
| 2M Ago | 2 | 1 | 2 | 0 | 0 |
| 3M Ago | 4 | 3 | 4 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $97.62, a high estimate of $110.00, and a low estimate of $87.00. Marking an increase of 3.43%, the current average surpasses the previous average price target of $94.38.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive Edwards Lifesciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Marie Thibault | BTIG | Maintains | Buy | $103.00 | $103.00 |
| Rick Wise | Stifel | Raises | Buy | $110.00 | $105.00 |
| Adam Maeder | Piper Sandler | Raises | Overweight | $98.00 | $95.00 |
| Danielle Antalffy | UBS | Raises | Neutral | $95.00 | $92.00 |
| Matt Miksic | Barclays | Raises | Overweight | $104.00 | $103.00 |
| Joshua Jennings | TD Cowen | Raises | Buy | $97.00 | $90.00 |
| Rick Wise | Stifel | Raises | Buy | $105.00 | $100.00 |
| Robbie Marcus | JP Morgan | Raises | Overweight | $100.00 | $90.00 |
| William Plovanic | Canaccord Genuity | Lowers | Hold | $87.00 | $89.00 |
| David Rescott | Baird | Lowers | Neutral | $87.00 | $88.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $101.00 | $96.00 |
| Matt Miksic | Barclays | Raises | Overweight | $103.00 | $99.00 |
| William Plovanic | Canaccord Genuity | Raises | Hold | $89.00 | $84.00 |
| Rick Wise | Stifel | Raises | Buy | $100.00 | $95.00 |
| Danielle Antalffy | UBS | Raises | Neutral | $92.00 | $90.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $96.00 | $95.00 |
| Richard Newitter | Truist Securities | Raises | Hold | $92.00 | $90.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $100.00 | $95.00 |
| David Rescott | Baird | Raises | Neutral | $88.00 | $83.00 |
| Marie Thibault | BTIG | Raises | Buy | $103.00 | $100.00 |
| Marie Thibault | BTIG | Maintains | Buy | $100.00 | $100.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Edwards Lifesciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Edwards Lifesciences compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Edwards Lifesciences's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Edwards Lifesciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Edwards Lifesciences analyst ratings.
Discovering Edwards Lifesciences: A Closer Look
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
A Deep Dive into Edwards Lifesciences's Financials
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Edwards Lifesciences displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 14.67%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Edwards Lifesciences's net margin excels beyond industry benchmarks, reaching 18.74%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Edwards Lifesciences's ROE stands out, surpassing industry averages. With an impressive ROE of 2.81%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.18%, the company showcases effective utilization of assets.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.07.
The Basics of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.